$RNA
Avidity Biosciences, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021013157 Filed on March 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q3
Revenue $2.704M $2.142M $1.746M
YoY Change 99.12% 48.24% 168.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.880M $4.820M $3.760M
YoY Change 200.0%
% of Gross Profit
Research & Development $20.68M $13.62M $9.460M
YoY Change 272.96% 85.53%
% of Gross Profit
Depreciation & Amortization $100.0K $110.0K $100.0K
YoY Change 0.0% -35.29%
% of Gross Profit
Operating Expenses $26.56M $18.44M $13.21M
YoY Change 253.77% 146.06% 125.61%
Operating Profit -$23.86M -$11.47M
YoY Change 287.92% 120.25%
Interest Expense $0.00 $20.00K $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $13.00K $18.00K $27.00K
YoY Change -80.0% -100.41% -101.85%
Pretax Income -$23.84M -$16.28M -$11.44M
YoY Change 291.46%
Income Tax
% Of Pretax Income
Net Earnings -$23.84M -$16.28M -$11.44M
YoY Change 291.85% 56.48% 71.55%
Net Earnings / Revenue -881.8% -759.8% -655.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$635.4K -$433.3K -$305.7K
COMMON SHARES
Basic Shares Outstanding 37.58M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $307.9M $328.1M $341.1M
YoY Change 246.73%
Cash & Equivalents $301.5M $321.5M $341.1M
Short-Term Investments $6.600M $6.700M
Other Short-Term Assets $4.000M $3.500M $3.200M
YoY Change 166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $312.0M $331.7M $344.3M
YoY Change 245.46% 246.67%
LONG-TERM ASSETS
Property, Plant & Equipment $2.187M $1.468M $1.295M
YoY Change 264.5% 132.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $364.0K $47.00K $417.0K
YoY Change -80.84% -92.17%
Total Long-Term Assets $2.802M $2.220M $1.836M
YoY Change 16.75% 80.34%
TOTAL ASSETS
Total Short-Term Assets $312.0M $331.7M $344.3M
Total Long-Term Assets $2.802M $2.220M $1.836M
Total Assets $314.8M $333.9M $346.1M
YoY Change 239.54% 244.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.40M $7.700M $6.300M
YoY Change 225.0%
Accrued Expenses $2.700M $3.200M $2.100M
YoY Change 170.0%
Deferred Revenue $4.357M $3.690M $5.220M
YoY Change -3.91%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $17.50M $14.59M $13.68M
YoY Change 54.87% 42.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $11.10M $13.10M $0.00
YoY Change -22.38% 29011.11%
Total Long-Term Liabilities $11.10M $13.10M $0.00
YoY Change -27.92% 621.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.50M $14.59M $13.68M
Total Long-Term Liabilities $11.10M $13.10M $0.00
Total Liabilities $28.64M $27.68M $25.97M
YoY Change 7.25% 0.48%
SHAREHOLDERS EQUITY
Retained Earnings -$90.40M -$66.54M
YoY Change 199.93%
Common Stock $376.5M $372.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $286.1M $306.2M $320.2M
YoY Change
Total Liabilities & Shareholders Equity $314.8M $333.9M $346.1M
YoY Change 239.54% 244.56%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$23.84M -$16.28M -$11.44M
YoY Change 291.85% 56.48% 71.55%
Depreciation, Depletion And Amortization $100.0K $110.0K $100.0K
YoY Change 0.0% -35.29%
Cash From Operating Activities -$19.68M -$13.08M -$9.110M
YoY Change 175.64% 20.0%
INVESTING ACTIVITIES
Capital Expenditures $525.0K -$230.0K -$850.0K
YoY Change 5150.0% 109.09%
Acquisitions
YoY Change
Other Investing Activities -$6.690M
YoY Change
Cash From Investing Activities -$525.0K -$6.930M -$850.0K
YoY Change 5150.0% 6200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities 17.00K 450.0K -1.340M
YoY Change -98.72% -99.37%
NET CHANGE
Cash From Operating Activities -19.68M -13.08M -9.110M
Cash From Investing Activities -525.0K -6.930M -850.0K
Cash From Financing Activities 17.00K 450.0K -1.340M
Net Change In Cash -20.19M -19.56M -11.30M
YoY Change 246.47% -132.55%
FREE CASH FLOW
Cash From Operating Activities -$19.68M -$13.08M -$9.110M
Capital Expenditures $525.0K -$230.0K -$850.0K
Free Cash Flow -$20.21M -$12.85M -$8.260M
YoY Change 182.6% 19.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
333898000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66540000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
306223000
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020Q2 dei Entity Public Float
EntityPublicFloat
887400000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
321462000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94578000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
6679000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3537000
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1098000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
331678000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
95676000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1468000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
631000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
600000
CY2019Q4 us-gaap Assets
Assets
96907000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
52042000
CY2020 rna Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering
ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering
120000
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37584600
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity File Number
EntityFileNumber
001-39321
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Trading Symbol
TradingSymbol
RNA
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 us-gaap Interest Expense
InterestExpense
209000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-241000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2490000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
15000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6787000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37602000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13462000
CY2020 us-gaap Operating Expenses
OperatingExpenses
51064000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-44277000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
75000
CY2020 dei Local Phone Number
LocalPhoneNumber
401-7900
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1336960
CY2020 dei City Area Code
CityAreaCode
(858)
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
10975 N. Torrey Pines Road
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2019 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
217524
CY2018 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
231810
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
37267000
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37569000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2989000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
379000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-65357000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96907000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2020Q4 us-gaap Liabilities
Liabilities
27675000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
38055000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
37267000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
134720000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37569000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2989000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
-43172000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2319000
CY2019 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
rna:CollaborationAndContractResearchRevenueMember
CY2018 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
rna:CollaborationAndContractResearchRevenueMember
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22185000
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1314000
CY2018 us-gaap Profit Loss
ProfitLoss
-11216000
CY2020 us-gaap Depreciation
Depreciation
373000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2308000
CY2019 us-gaap Profit Loss
ProfitLoss
-24734000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3690000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2774000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1770000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45000
CY2019Q4 us-gaap Liabilities
Liabilities
27544000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
372764000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2020 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
rna:CollaborationAndContractResearchRevenueMember
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14539000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8436000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5112000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2441000
CY2019 us-gaap Operating Expenses
OperatingExpenses
19651000
CY2018 us-gaap Operating Expenses
OperatingExpenses
10877000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-17332000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-10498000
CY2020 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
206000
CY2019 us-gaap Interest Expense
InterestExpense
7387000
CY2018 us-gaap Interest Expense
InterestExpense
718000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-78000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7402000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-718000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44355000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-24734000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-11216000
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44360000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24734000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11216000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.05
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.12
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.53
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21663000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2713000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2477000
CY2017Q4 us-gaap Members Equity
MembersEquity
-30072000
CY2018 rna Partners Capital Units Issued During Period Value Unit Options Exercised
PartnersCapitalUnitsIssuedDuringPeriodValueUnitOptionsExercised
67000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
32000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
60000
CY2018Q4 us-gaap Members Equity
MembersEquity
-41129000
CY2019 rna Partners Capital Units Issued During Period Value Unit Options Exercised
PartnersCapitalUnitsIssuedDuringPeriodValueUnitOptionsExercised
38000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
17000
CY2019 rna Net Income Loss To Date Of Conversion
NetIncomeLossToDateOfConversion
-2549000
CY2019 rna Stock Issued During Period Value Stock Options Exercised Net Of Repurchases
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfRepurchases
26000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
36000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
389000
CY2019 rna Net Income Loss Excluding Conversion
NetIncomeLossExcludingConversion
-22185000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
136920000
CY2020 rna Stock Issued During Period Value Stock Options Exercised Net Of Repurchases
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfRepurchases
22000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
444000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
70000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4310000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000
CY2020 us-gaap Profit Loss
ProfitLoss
-44355000
CY2018 rna Proceeds From Issuance Of Long Term Debt Excluding Convertible Notes
ProceedsFromIssuanceOfLongTermDebtExcludingConvertibleNotes
1994000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3100000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
18940000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37117000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9655000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6693000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1092000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
235000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000
CY2020 rna Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0
CY2019 rna Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0
CY2018 rna Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-7000
CY2019 us-gaap Depreciation
Depreciation
348000
CY2018 us-gaap Depreciation
Depreciation
383000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4310000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
406000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
60000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-9000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
29000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
71000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
73000
CY2020 rna Noncash Interest Expense
NoncashInterestExpense
110000
CY2019 rna Noncash Interest Expense
NoncashInterestExpense
7027000
CY2018 rna Noncash Interest Expense
NoncashInterestExpense
374000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2444000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
949000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5749000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
436000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
780000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1838000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1010000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
127000
CY2020 rna Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
289000
CY2019 rna Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-80000
CY2018 rna Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
0
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7785000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-235000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49000
CY2020 rna Proceeds From Issuance Of Common Stock In Initial Public Offering Gross
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingGross
298080000
CY2019 rna Proceeds From Issuance Of Common Stock In Initial Public Offering Gross
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingGross
0
CY2018 rna Proceeds From Issuance Of Common Stock In Initial Public Offering Gross
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingGross
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
24026000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
162000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
444000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2020 rna Proceeds From Issuance Of Long Term Debt Excluding Convertible Notes
ProceedsFromIssuanceOfLongTermDebtExcludingConvertibleNotes
0
CY2019 rna Proceeds From Issuance Of Long Term Debt Excluding Convertible Notes
ProceedsFromIssuanceOfLongTermDebtExcludingConvertibleNotes
0
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4683000
CY2018 rna Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering
ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering
0
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
321713000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
571000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
322000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
291000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
936000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
807000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
118000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
43000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
136920000
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2018 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2020 rna Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes
IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes
0
CY2019 rna Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes
IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes
29510000
CY2018 rna Issuance Of Convertible Preferred Stock Upon Conversion Of Convertible Notes
IssuanceOfConvertiblePreferredStockUponConversionOfConvertibleNotes
0
CY2019 rna Reclassification Of Warrant Liability To Equity Due To Adjustment From Preferred Stock Warrant To Common Stock Warrant Upon Completion Of Initial Public Offering
ReclassificationOfWarrantLiabilityToEquityDueToAdjustmentFromPreferredStockWarrantToCommonStockWarrantUponCompletionOfInitialPublicOffering
0
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2800000
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2020 rna Distributions To Members
DistributionsToMembers
0
CY2019 rna Distributions To Members
DistributionsToMembers
-106000
CY2018 rna Distributions To Members
DistributionsToMembers
0
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
2200000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
72623000
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19451000
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2988000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272037000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89233000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5144000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
227135000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
91488000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4560000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94578000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3090000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7650000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
454000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2020Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2019-01-01
CY2020 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
123285
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6486
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements<font style="letter-spacing:-0.45pt;"> </font>are<font style="letter-spacing:-0.35pt;"> </font>prepared<font style="letter-spacing:-0.2pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.1pt;">accordance</font><font style="letter-spacing:-0.35pt;"> </font>with<font style="letter-spacing:-0.15pt;"> GAAP, which</font><font style="letter-spacing:-0.45pt;"> </font>requires<font style="letter-spacing:-0.5pt;"> the Company </font>to<font style="letter-spacing:-0.2pt;"> </font>make<font style="letter-spacing:-0.3pt;"> </font>estimates <font style="letter-spacing:0.1pt;">and assumptions </font><font style="letter-spacing:0.15pt;">that </font><font style="letter-spacing:0.1pt;">impact </font><font style="letter-spacing:0.15pt;">the </font>reported <font style="letter-spacing:0.15pt;">amounts of </font>assets, <font style="letter-spacing:0.15pt;">liabilities, </font><font style="letter-spacing:0.1pt;">revenues and expenses and </font><font style="letter-spacing:0.15pt;">the </font><font style="letter-spacing:0.1pt;">disclosure </font><font style="letter-spacing:0.15pt;">of </font><font style="letter-spacing:0.2pt;">contingent </font>assets <font style="letter-spacing:0.1pt;">and </font><font style="letter-spacing:0.15pt;">liabilities in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements </font>relate <font style="letter-spacing:0.1pt;">to</font> revenue recognition, stock-based compensation, and accrued research and development costs. <font style="letter-spacing:0.15pt;">Although </font><font style="letter-spacing:0.1pt;">these </font>estimates are based <font style="letter-spacing:0.15pt;">on the </font><font style="letter-spacing:0.1pt;">Company&#8217;s</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.15pt;">knowledge</font><font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:0.15pt;">of</font><font style="letter-spacing:-0.65pt;"> </font>current<font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:0.15pt;">events</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.1pt;">and</font><font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:0.15pt;">actions</font><font style="letter-spacing:-0.45pt;"> </font>it<font style="letter-spacing:-0.2pt;"> </font>may<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:0.15pt;">undertake</font><font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:0.15pt;">the</font><font style="letter-spacing:-0.3pt;"> </font>future,<font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:0.1pt;">actual</font><font style="letter-spacing:-0.2pt;"> </font>results<font style="letter-spacing:-0.45pt;"> </font>may<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:0.1pt;">ultimately</font><font style="letter-spacing:-0.15pt;"> </font>materially<font style="letter-spacing:-0.1pt;"> </font>differ<font style="letter-spacing:-0.65pt;"> </font>from<font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:0.1pt;">these</font><font style="letter-spacing:-0.3pt;"> </font>estimates <font style="letter-spacing:0.1pt;">and</font><font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:0.1pt;">assumptions.</font></p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity.</p>
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
6684000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
6679000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3447000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2274000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1979000
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
938000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
17000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1643000
CY2019Q4 rna Long Term Debt Current Gross
LongTermDebtCurrentGross
2800000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
135000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
208000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
220000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
188000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
1000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
982000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44000
CY2019Q4 rna Long Term Debt Noncurrent Gross
LongTermDebtNoncurrentGross
1400000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
163000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
382000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
453000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.46
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
302000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
302000
CY2020 rna Short Term Lease Rent Expense
ShortTermLeaseRentExpense
36000
CY2019 rna Short Term Lease Rent Expense
ShortTermLeaseRentExpense
6000
CY2020 rna Lease Rent Expense
LeaseRentExpense
489000
CY2019 rna Lease Rent Expense
LeaseRentExpense
308000
CY2018 rna Lease Rent Expense
LeaseRentExpense
302000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M18D
CY2019Q4 rna Accrued End Of Term Fees Noncurrent
AccruedEndOfTermFeesNoncurrent
374000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
4000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2291000
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
119000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
4544000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
51000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3788000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
556000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.08
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.24
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 4, 2020, the Company effected a one-for-2.1095 reverse stock split of its common stock (the Reverse Stock Split).
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2.1095
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
328100000
CY2020 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2018 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.027
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.45
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.24
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3858
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19545
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.06
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2019Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
25000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.24
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
65082000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13491000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.029
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
Currently, the Company is only party to non-cancellable office and laboratory space operating leases and a short-term office lease. Under the relevant guidance, the Company recognizes operating lease right-of-use (ROU) assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 5.5%, and amortizes the ROU assets and liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company’s short-term lease is not subject to recognition of an ROU asset or liability or straight-line lease expense requirements.
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 rna Retained Earnings Accumulated Deficit Reclassified To Additional Paid In Capital
RetainedEarningsAccumulatedDeficitReclassifiedToAdditionalPaidInCapital
44100000
CY2019Q4 rna Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
37267000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
138970000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1667000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.88
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.63
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.30
CY2020Q4 rna Share Based Compensation Arrangement By Share Based Payment Award Number Of Unvested Shares Early Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnvestedSharesEarlyExercised
69359
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.88
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.84
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.84
CY2019Q4 rna Share Based Compensation Arrangement By Share Based Payment Award Number Of Unvested Shares Early Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnvestedSharesEarlyExercised
194729
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.003
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.014
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.024
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.015
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.83
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.92
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4443000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
153000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
179000
CY2020Q4 rna Deferred Tax Assets Intangibles And Fixed Assets
DeferredTaxAssetsIntangiblesAndFixedAssets
2483000
CY2019Q4 rna Deferred Tax Assets Intangibles And Fixed Assets
DeferredTaxAssetsIntangiblesAndFixedAssets
2721000
CY2020Q4 rna Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
263000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4275000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1855000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
438000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
7508000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4310000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
406000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6936000
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20951000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9315000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5194000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3004000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1057000
CY2020 rna Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
1000
CY2019 rna Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
14000
CY2019 rna Income Tax Reconciliation Book Income Loss For Pre Conversion Period
IncomeTaxReconciliationBookIncomeLossForPreConversionPeriod
527000
CY2019 rna Income Tax Reconciliation Interest On Convertible Notes
IncomeTaxReconciliationInterestOnConvertibleNotes
445000
CY2019 rna Income Tax Reconciliation Realized Gain On Conversion Of Convertible Notes
IncomeTaxReconciliationRealizedGainOnConversionOfConvertibleNotes
958000
CY2020 rna Income Tax Reconciliation Reserve For Uncertain Tax Positions
IncomeTaxReconciliationReserveForUncertainTaxPositions
398000
CY2019 rna Income Tax Reconciliation Reserve For Uncertain Tax Positions
IncomeTaxReconciliationReserveForUncertainTaxPositions
140000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1639000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
584000
CY2019 rna Income Tax Reconciliation Deferred Tax Recognized Upon Conversion
IncomeTaxReconciliationDeferredTaxRecognizedUponConversion
3076000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13488000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7827000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
71000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11277000
CY2019Q4 rna Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
265000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
969000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
160000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21443000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8038000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21316000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7827000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
127000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
211000
CY2020Q4 rna Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
127000
CY2019Q4 rna Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
211000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
127000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
211000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13500000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
156000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
446000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
156000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
62000
CY2020 rna Unrecognized Tax Benefits Other True Up Adjustment
UnrecognizedTaxBenefitsOtherTrueUpAdjustment
7000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
11909000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
671000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1358000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1541000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1746000
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2142000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
13212000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
18435000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
65000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-188000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27000
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6085000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10556000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11439000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-16275000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.14
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
224000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
650000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1445000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
2174000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
4129000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
5856000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
7492000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-375000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1211000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1462000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4354000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2549000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5116000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6668000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-10401000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.89
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.43
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.75

Files In Submission

Name View Source Status
0001564590-21-013157-index-headers.html Edgar Link pending
0001564590-21-013157-index.html Edgar Link pending
0001564590-21-013157.txt Edgar Link pending
0001564590-21-013157-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gasjkscxs0ac000001.jpg Edgar Link pending
gasjkscxs0ac000042.jpg Edgar Link pending
gasjkscxs0ac000044.jpg Edgar Link pending
gasjkscxs0ac000046.jpg Edgar Link pending
gasjkscxs0ac000055.jpg Edgar Link pending
gasjkscxs0ac000057.jpg Edgar Link pending
gasjkscxs0ac000075.jpg Edgar Link pending
gasjkscxs0ac000077.jpg Edgar Link pending
gasjkscxs0ac000079.jpg Edgar Link pending
gasjkscxs0ac000081.jpg Edgar Link pending
gasjkscxs0ac000083.jpg Edgar Link pending
gasjkscxs0ac000085.jpg Edgar Link pending
gasjkscxs0ac000087.jpg Edgar Link pending
ggtfgleeai5s000001.jpg Edgar Link pending
gpwulql2zre5000001.jpg Edgar Link pending
gpwulql2zre5000002.jpg Edgar Link pending
gpwulql2zre5000003.jpg Edgar Link pending
gpwulql2zre5000004.jpg Edgar Link pending
gpwulql2zre5000005.jpg Edgar Link pending
gpwulql2zre5000006.jpg Edgar Link pending
gpwulql2zre5000007.jpg Edgar Link pending
gpwulql2zre5000008.jpg Edgar Link pending
gpwulql2zre5000009.jpg Edgar Link pending
gpwulql2zre5000010.jpg Edgar Link pending
gpwulql2zre5000011.jpg Edgar Link pending
gpwulql2zre5000012.jpg Edgar Link pending
gpwulql2zre5000013.jpg Edgar Link pending
gpwulql2zre5000014.jpg Edgar Link pending
gpwulql2zre5000015.jpg Edgar Link pending
gpwulql2zre5000016.jpg Edgar Link pending
gpwulql2zre5000017.jpg Edgar Link pending
gpwulql2zre5000018.jpg Edgar Link pending
gpwulql2zre5000019.jpg Edgar Link pending
gpwulql2zre5000020.jpg Edgar Link pending
gpwulql2zre5000021.jpg Edgar Link pending
gpwulql2zre5000022.jpg Edgar Link pending
gpwulql2zre5000023.jpg Edgar Link pending
gpwulql2zre5000024.jpg Edgar Link pending
gpwulql2zre5000025.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rna-10k_20201231.htm Edgar Link pending
rna-20201231.xml Edgar Link completed
rna-20201231.xsd Edgar Link pending
rna-20201231_cal.xml Edgar Link unprocessable
rna-20201231_def.xml Edgar Link unprocessable
rna-20201231_lab.xml Edgar Link unprocessable
rna-20201231_pre.xml Edgar Link unprocessable
rna-ex1010_622.htm Edgar Link pending
rna-ex1014_621.htm Edgar Link pending
rna-ex104_840.htm Edgar Link pending
rna-ex231_620.htm Edgar Link pending
rna-ex311_9.htm Edgar Link pending
rna-ex312_8.htm Edgar Link pending
rna-ex321_7.htm Edgar Link pending
rna-ex322_6.htm Edgar Link pending
rna-ex43_839.htm Edgar Link pending
Show.js Edgar Link pending